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Abstract
Background—BRCA1 and BRCA2 mutation carriers are at substantially increased risk for 
developing breast and ovarian cancer. The incomplete penetrance coupled with the variable age at 
diagnosis in carriers of the same mutation suggests the existence of genetic and non-genetic 
modifying factors. In this study we evaluated the putative role of variants in many candidate 
modifier genes.
Methods—Genotyping data from 15,252 BRCA1 and 8,211 BRCA2 mutation carriers, for known 
variants (n=3,248) located within or around 445 candidate genes, were available through the 
iCOGS custom-designed array. Breast and ovarian cancer association analysis was performed 
within a retrospective cohort approach.
Results—The observed p-values of association ranged between 0.005–1.000. None of the 
variants was significantly associated with breast or ovarian cancer risk in either BRCA1 or BRCA2 
mutation carriers, after multiple testing adjustments.
Conclusion—There is little evidence that any of the evaluated candidate variants act as 
modifiers of breast and/or ovarian cancer risk in BRCA1 or BRCA2 mutation carriers.
Impact—Genome-wide association studies have been more successful at identifying genetic 
modifiers of BRCA1/2 penetrance than candidate gene studies.
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Introduction
Germline BRCA1 or BRCA2 mutations substantially increase the risk of developing breast 
and ovarian cancer over those of the general population (1). The penetrance is incomplete 
and combined with the observed variability in age at cancer diagnosis in carriers of identical 
mutations, suggests the existence of genetic and/or environmental modifying factors. Direct 
evidence for genetic modifiers of breast and ovarian cancer risk for BRCA1 and BRCA2 
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mutation carriers has been provided through genome-wide association studies (GWAS) (2). 
In parallel, multiple variants in candidate genes that affect BRCA1 or BRCA2 protein 
expression, act along the same biological pathways, or physically interact with BRCA1 or 
BRCA2 proteins have been evaluated as putative modifiers of BRCA1/2 mutations 
(reviewed in 3). However, only a handful of these factors were confirmed and independently 
validated as “true modifiers” (4). The aim of the present study was to assess the putative 
modifier effect of 3,248 sequence alterations in 445 candidate genes on breast/ovarian 
cancer risk in 23,463 BRCA1 and BRCA2 mutation carriers.
Materials and methods
Recruitment and data collection
All study participants were women, >18 years old, carrying a deleterious germline mutation 
in either BRCA1 or BRCA2. DNA samples and phenotypic data were submitted by 54 study 
centers participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) 
(5). Recruitment strategies, clinical, demographic, and phenotypic data collected from each 
participant, and quality control procedures, have previously been reported (4,5). All study 
participants took part in research studies at the parent institutions under ethically-approved 
protocols as detailed (4,5).
Sequence variants genotyped
DNA samples were genotyped using the custom Illumina iCOGS array which included 
211,155 single nucleotide polymorphisms (SNPs) as previously described (http://
www.nature.com/icogs/primer/cogs-project-and-design-of-the-icogs-array/; 6). We report 
results from 3,248 SNPs from 445 candidate genes proposed by 17 PIs (=projects). The 
rationale for selecting the SNPs or genes as candidate cancer risk modifiers in BRCA1 and 
BRCA2 mutation carriers is shown in Table 1. The list of SNPs included in the study and 
their gene location (if any) is provided in Supplementary Table 1. Genotyping quality 
control procedures were carried out as reported elsewhere (6).
Statistical analysis
Associations were evaluated within a retrospective cohort framework, by modeling the 
retrospective likelihood of the observed genotypes conditional on the disease phenotypes 
(4,7). The associations between genotype and breast or ovarian cancer risk were assessed 
using the 1 d.f. score test statistic based on this retrospective likelihood while accounting for 
the non-independence among related individuals (8). All analyses were stratified by country 
of residence and used calendar-year and cohort-specific breast and ovarian cancer incidence 
rates for BRCA1 and BRCA2 mutation carriers. Details are provided elsewhere (2).
Results
A total of 23,463 mutation carriers were included (15,252 BRCA1, 8,211 BRCA2 carriers), 
12,127 with breast cancer (7,797 BRCA1, 4,330 BRCA2 carriers), 3,093 with ovarian 
cancer (2,462 BRCA1, 631 BRCA2 carriers), and 9,220 cancer-free carriers (5,788 BRCA1, 
3,432 BRCA2 carriers). All 3,248 SNPs were tested as genetic risk modifiers for both breast 
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and ovarian cancer in BRCA1 and BRCA2 mutation carriers depending on the selection 
rationale (Table 1). For each SNP, the number of individuals with genotype data, minor 
allele frequencies (MAF), values of the X2 score test statistic, approximate hazard ratio (HR) 
estimates based on the score test statistic (7), overall P values and retrospective likelihood 
HR are shown in Supplementary Table 2. Since project 12 was based on the hypothesis that 
estrogens contribute to breast cancer pathogenesis, these 139 SNPs were stratified by 
somatic estrogen receptor status (Supplementary Table 3). None of the SNPs tested showed 
significant evidence of association with breast and/or ovarian cancer risk, as a single tested 
variant or after adjusting for mutiple testing. Indeed, there were fewer associations at a 
nominal P<0.05 or P<0.01 than would be expected by chance (Table 2).
Discussion
In this study, there were no discernible effects for the genotyped SNPs on either breast or 
ovarian cancer risk in BRCA1 or BRCA2 mutation carriers. Despite the lack of evidence of 
association between these specific variants and breast/ovarian cancer risk for BRCA1/
BRCA2 mutation carriers, these genes may still modify cancer risk by other sequence 
alterations that are not represented on the iCOGS platform, by epigenetic alterations in gene 
expression, or in combination and interaction with other polymorphisms, that in concert 
have an overall effect on cancer risk.
In conclusion, the genotyped SNPs in the candidate modifier genes evaluated here have no 
major role in breast or ovarian cancer risk modification in either BRCA1 or BRCA2 mutation 
carriers. Our results suggest that a candidate gene approach where the selected SNPs have 
little a priori biological plausibility is of limited value in identifying modifier genes, unlike 
agnostic genome-wide associations which have been more successful (8). Applying more 
advanced technologies, (whole exome/genome sequencing) and targeting phenotypically 
distinct mutation carriers may also offer further insights into modifier genes’ identity.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 2
Observed and expected number of SNPs with p-values <0.05 and <0.01
Category Tumor Number of SNPs tested* Number of SNPs with p-value<0.01 (expected)
Number of SNPs with p-value<0.05 
(expected)
BRCA1 BrCa 3232 25 (32) 202 (162)
BRCA1 OvCa 3160 13 (32) 146 (158)
BRCA2 BrCa 3230 5 (32) 96 (161)
BRCA2 OvCa 3157 6 (32) 131 (159)
*Not all the 3,248 SNPs were tested in each category/tumor group
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